News
ORGS
0.5100
+0.22%
0.0011
BRIEF-Orgenesis Board Says Financial Statements For Qtrs Ended March 31, 2023, June 30, 2023, Sept 30, 2023, To No Longer Be Relied Upon
Orgenesis Board Says Financial Statements For Qtrs Ended March 31, 2023, Should No Longer Be Relied Upon. Orgenesis Inc says financial statements should no longer be relied on. The company says the statements are for the period of March 31 to September 30, 20 23.
Reuters · 2d ago
ORGENESIS INC - LOOKING FORWARD, OUR FIRST MAJOR STEP IN TRANSFORMATION WAS RECENT TRANSACTION TO REGAIN 100% OWNERSHIP OF OCTOMERA
Reuters · 2d ago
Press Release: Orgenesis Provides Year End -2-
Undertake no obligation to revise or update any forward-looking statement for any reason. Orgenesis has a total of 4,076 million dollars in cash and cash equivalents as of December 31, 2018. The company has a long-term target of $5,000 million. The Company has no debt.
Dow Jones · 2d ago
ORGENESIS- BOARD DETERMINED CO'S FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, 2023, JUNE 30, 2023, SEPT 30, 2023, SHOULD NO LONGER BE RELIED UPON
Reuters · 2d ago
Orgenesis Provides Year End Business Update
Barchart · 2d ago
Weekly Report: what happened at ORGS last week (0408-0412)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Rallybio shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by 10.52% during the session.
Benzinga · 04/10 20:31
12 Health Care Stocks Moving In Wednesday's Intraday Session
Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 61.6% to $1.83 during Wednesday's regular session. Orgenesis stock rose 27.83% and Jaguar Health shares rose 32.22% during the same period. Telomir Pharmaceuticals and Orgen Genesis were the biggest gainers in the company's stock.
Benzinga · 04/10 16:31
Germfree And Orgenesis Announce Asset Purchase And Strategic Partnership Intended To Revolutionize Cell And Gene Therapy Through Decentralized Production And Global Accessibility
Germfree and Orgenesis Inc. Announce a strategic partnership to transform the production of cell and gene therapies. The partnership seeks to significantly reduce the production costs of life-saving treatments. Germfree's modular cleanroom infrastructure and services will be used to co-market the decentralized processing of cell therapies globally. The two companies are a global leader in decentralizing cell and Gene therapies.
Benzinga · 04/10 16:01
GERMFREE AND ORGENESIS ANNOUNCE ASSET PURCHASE AND STRATEGIC PARTNERSHIP INTENDED TO REVOLUTIONIZE CELL AND GENE THERAPY THROUGH DECENTRALIZED PRODUCTION AND GLOBAL ACCESSIBILITY
Reuters · 04/10 16:00
Weekly Report: what happened at ORGS last week (0401-0405)?
Weekly Report · 04/08 10:35
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. AN2 Therapeutics (NASdaq:ANTX) shares rose by 6.76%. Candel Therapeutic stock moved upwards by 4.99% during the day. Losers AcordaTherapeutics and WAVE Life Sciences lost 8.9% and 7.1% respectively.
Benzinga · 04/04 20:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
ARCA biopharma (NASDAQ:ABIO) stock moved upwards by 124.6% to $3.84 during Wednesday's pre-market session. Kintara Therapeutics and Aesthetic Medical Intl were the biggest gainers. SINTX Techs stock declined by 21.0% during the day.
Benzinga · 04/03 12:09
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Stryve Foods, Inc. (NASDAQ:SNAX) fell sharply following a fourth-quarter revenue miss. The company posted adjusted loss of $1.90 per share. VivoPower International PLC shares surged 315% to $6.10 after the company announced a merger.
Benzinga · 04/02 17:23
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. MSP Recovery (NASdaq:LIFW) shares moved upwards by 33.26%. Q4 earnings report came out 4 days ago. Losers Acorda Therapeutics and Gritstone Bio.
Benzinga · 04/02 16:31
ORGENESIS INC - EXPECTS TO CONCLUDE & DISCLOSE IN THE 2023 FORM 10-K THAT THERE IS SUBSTANTIAL DOUBT ABOUT ITS ABILITY TO CONTINUE AS A GOING CONCERN
Reuters · 04/01 20:23
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Nuvve Holding Corp. (NASDAQ:NVVE) fell sharply after the company reported worse-than-expected fourth-quarter financial results. The company posted a quarterly loss of $6.98 per share. Vast Renewables Limited shares jumped 179% to $8.62 after jumping 39% on Thursday.
Benzinga · 04/01 18:31
Weekly Report: what happened at ORGS last week (0325-0329)?
Weekly Report · 04/01 10:35
Weekly Report: what happened at ORGS last week (0318-0322)?
Weekly Report · 03/25 10:37
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 03/24 12:01
More
Webull provides a variety of real-time ORGS stock news. You can receive the latest news about Orgenesis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORGS
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.